Clinical Trials Logo

Clinical Trial Summary

As the most common subtype of liver cancer (85% ~ 90%), HCC is highly malignant; thus, one of the crucial issues in HCC management is an effective therapy for tumors at an early stage, which is vital for improving the prognosis of patients. For ≤3cm HCC, ablation has been recommended by international guidelines as a first-line or alternative treatment because of similar survival outcomes and milder liver function injury with liver resection (LR). However, the appropriate treatment options for 3-5cm HCC remain controversial. Thus, none of the international guidelines recommend ablation as a first-line treatment for 3-5cm HCC. In the past few decades, treatment for HCC has tended to be less invasive, have fewer complications, and have higher cost-effectiveness. Compared with LR, laparoscopic Hepatectomy (LH) demonstrates the advancement of minimal invasion. As another minimally invasive technique for HCC, Microwave Ablation (MWA) has the potential to eradicate larger HCCs with larger coagulation areas and is less affected by the heat sink effect caused by vessels around the tumor. Many studies have identified the potential advantages of MWA over other ablation techniques. However, to date, no clinical studies have compared the efficacy of LH and MWA therapies for 3-5cm HCC with periodic progression.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05796700
Study type Interventional
Source Chinese PLA General Hospital
Contact
Status Completed
Phase N/A
Start date January 1, 2008
Completion date December 30, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT04025840 - Perioperative Epidural Block and Dexamethasone in Pancreatic Cancer Surgery Phase 4
Completed NCT04111926 - Intraoperative Dexmedetomidine and Long-term Outcomes in Elderly After Major Surgery Phase 4
Recruiting NCT04101760 - Granulocyte Colony Stimulating Factor for for the Prevention of Febrile Neutropenia in Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03342300 - Pegylated Liposomal Doxorubicin Versus Pirarubicin Plus Ifosfamide, Dacarbazine in Locally Advanced, Unresectable or Metastatic Soft-tissue Sarcoma Phase 2/Phase 3
Recruiting NCT03910140 - TILA-TACE in Treatment of Hepatocellular Carcinoma N/A
Completed NCT03923400 - Jejunoileal vs Gastric GIST in the Era of Imatinib.
Withdrawn NCT02201381 - Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer Phase 3
Recruiting NCT05392257 - Efficacy and Safety of Rituximab Plus Zanubrutinib and Lenalidomide for Relapsed and Refractory Diffuse Large B Cell Lymphoma, a Multicenter, Open and Prospective Clinical Trial Phase 2
Recruiting NCT05310305 - PD-1 Antibody and Radiotherapy for Recurrent Cervical Cancer
Recruiting NCT05310370 - HRD and Resistance to PAPPi in EOC Patients
Recruiting NCT05310357 - Chromosomal Instability in Ovarian Cancer
Active, not recruiting NCT04245644 - Efficacy of Chemopreventive Agents on Disease-free and Overall Survival in Patients With Pancreatic Ductal Adenocarcinoma: The CAOS Study
Recruiting NCT04245410 - Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma
Completed NCT02980185 - Laparoscopy for Primary Cytoreductive Surgery in Advanced Ovarian Cancer N/A
Recruiting NCT03967457 - Comprehensive Study on the Quality of Life in Cervical Cancer Patients
Recruiting NCT04050787 - Spleen-Preserving No. 10 Lymph Node Dissection in Gastric Cancer N/A
Recruiting NCT03892577 - Real-world Study for Patients With Advanced Hepatobiliary Tumors
Completed NCT03726021 - Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer Phase 2
Not yet recruiting NCT02942238 - Standardization of Laparoscopic Surgery for Right Hemi Colon Cancer (SLRC) N/A
Not yet recruiting NCT01236989 - Prognostic Impact of Anatomical Resection Vs. Non-anatomical Resection for HCC N/A